Britain and America have agreed to a important trade agreement that will ensure no levies on UK pharmaceutical products entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that tariffs on these vital exports will be held at zero for a duration of three years.
This deal follows earlier statements to hike duties on patented drug imports, with increases mentioned as high as double the cost.
"This arrangement with the United Kingdom strengthens the worldwide climate for innovative medicines and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Importance
Drugs constitute one of the Britain's largest goods shipped to the United States, which is clearly the biggest destination for large UK drugmakers.
Export figures reveal that in the 12 months prior to last September, the UK exported drugs worth billions to the US. This amount made up 17.4% of British export trade in that period.
"This guarantee safeguards work, boosts funding and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Key NHS Changes
The deal includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to increase total NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments were more than 20%.
Industry Background
This agreement takes place against a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
This friction were heightened by arguments that American consumers were paying significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a percentage of its total funding over the previous ten-year period.
